Chemify raises $50M+ Series B to scale molecule-making businessnews2025-10-21T12:00:17+00:00October 21st, 2025|Endpoints News|
Merck KGaA is open to more acquisitions, but not for its CDMO unitnews2025-10-16T15:18:38+00:00October 16th, 2025|Endpoints News|
AstraZeneca opens $445M expansion of Lokelma factory; Avidity Bio delays BLA for Duchenne drugnews2025-10-16T14:16:53+00:00October 16th, 2025|Endpoints News|
BioNTech to get up to €95M in EU funding for a mRNA vaccine site in Africa news2025-10-15T16:07:33+00:00October 15th, 2025|Endpoints News|
FDA hands OAI classification to Novo Nordisk’s troubled Indiana sitenews2025-10-13T15:38:49+00:00October 13th, 2025|Endpoints News|
Ypsomed spends $248M to gain its first US manufacturing site news2025-10-10T10:50:38+00:00October 10th, 2025|Endpoints News|
AstraZeneca breaks ground on Virginia plant after Trump warns drugmakers to build or face tariffsnews2025-10-09T16:30:13+00:00October 9th, 2025|Endpoints News|
Xspray gets CRL over third-party production issues; Oxford Biomedica buys site from Resilience subsidiarynews2025-10-09T13:01:01+00:00October 9th, 2025|Endpoints News|
UK drafts plans to pay up to 25% more for meds to appease drugmakersnews2025-10-08T17:10:21+00:00October 8th, 2025|Endpoints News|
Lawyers scramble on how to advise clients on Trump’s 100% pharma tariff threat news2025-10-08T16:13:10+00:00October 8th, 2025|Endpoints News|
